Oncomed Pharmaceuticals Stock Price Down 3.3% Following Insider Selling (OMED)
Oncomed Pharmaceuticals (NASDAQ:OMED) shares fell 3.3% during trading on Monday following insider selling activity, Analyst RN reports. The company traded as low as $19.32 and last traded at $19.32, with a volume of 54,922 shares changing hands. The stock had previously closed at $19.97.
Specifically, Insider Austin Gurney unloaded 4,000 shares of the stock on the open market in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $20.00, for a total transaction of $80,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Several analysts have recently commented on the stock. Analysts at Zacks downgraded shares of Oncomed Pharmaceuticals from a “neutral” rating to an “underperform” rating in a research note on Tuesday, August 12th. They now have a $15.00 price target on the stock. Analysts at Mizuho reiterated a “buy” rating on shares of Oncomed Pharmaceuticals in a research note on Friday, June 13th.
The stock has a 50-day moving average of $20.76 and a 200-day moving average of $26.17. The company’s market cap is $582.7 million.
Oncomed Pharmaceuticals (NASDAQ:OMED) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.53) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.03) by $0.50. The company had revenue of $6.00 million for the quarter, compared to the consensus estimate of $21.28 million. On average, analysts predict that Oncomed Pharmaceuticals will post $-1.35 earnings per share for the current fiscal year.
OncoMed Pharmaceuticals, Inc (NASDAQ:OMED) is a clinical development-stage biopharmaceutical company.
Receive News & Ratings for Oncomed Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.